About Reflux Pharmaceuticals
Reflux Pharmaceuticals is a Healthcare company based in Navi Mumbai (India) founded in 2020. Active pharmaceutical ingredients and intermediates are manufactured by Reflux Pharmaceuticals. Its Indian entity Reflux Pharmaceuticals Private Limited reported revenue of ₹20.56 Cr. Reflux Pharmaceuticals offers products and services including Tolfenamic Acid and Flavoxate HCl. Its focus areas include Traditional Pharmaceuticals.
Company details
Reflux Pharmaceuticals was established in 2020 and is based in Navi Mumbai, India. The company operates within the pharmaceutical sector, focusing on the production of active pharmaceutical ingredients (APIs) and chemical intermediates. These materials are supplied to support drug manufacturing processes. Operations emphasize quality-controlled synthesis and formulation, serving clients in the global healthcare industry. The firms activities align with regulatory standards for pharmaceutical components.
- Headquarters Navi Mumbai, India
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website refluxpharmaceuticals.com
- Legal Name Reflux Pharmaceuticals Private Limited
- Date of Incorporation 03 Feb, 2020
- Jurisdiction Thane, Maharashtra, India
- Annual Revenue₹20.56 Cr
FY 2025 · +15% YoY
- Net Profit₹57.3 Lakh
FY 2025 · 3% margin
- EBITDA₹98 Lakh
FY 2025 · 5% margin
- Investors
Associated legal entities of Reflux Pharmaceuticals
Reflux Pharmaceuticals operates through Reflux Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Reflux Pharmaceuticals Private Limited CIN U74999MH2020PTC337046 | Active | 03 Feb 2020 | Thane, Maharashtra | ₹20.6 Cr | 3 | View details |
Products & Services of Reflux Pharmaceuticals
Reflux Pharmaceuticals offers a comprehensive portfolio of products and services, including Tolfenamic Acid and Flavoxate HCl.
Tolfenamic Acid is produced as a non-steroidal anti-inflammatory drug for pharmaceutical applications.
Flavoxate HCl is manufactured for anti-spasmodic uses and treatment of urinary incontinence.
Funding Insights of Reflux Pharmaceuticals
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Reflux Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2023 | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Reflux Pharmaceuticals
Reflux Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Eiko LifeSciences Limited.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturing and exporting of speciality chemicals and pharma intermediates in India. | eikolifesciences.com |
Investor details for Reflux Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Reflux Pharmaceuticals Private Limited (Reflux Pharmaceuticals)
Reflux Pharmaceuticals Private Limited is the primary company behind Reflux Pharmaceuticals. The board of Reflux Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Amit Kumar Ghosh, appointed in 2020.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Amit Kumar Ghosh DIN 07722632 | Director | 03 Feb 2020 | 6 yrs 8 mo | Reflux Pharmaceuticals Private Limited |
| Sandeep Khandu Tekle DIN 07719306 | Director | 03 Feb 2020 | 6 yrs 8 mo | Reflux Pharmaceuticals Private Limited |
| Jaid Ismail Kojar DIN 06646692 | Nominee Director | 29 Jul 2024 | 2 yrs 2 mo | Reflux Pharmaceuticals Private Limited |
Financials of Reflux Pharmaceuticals
Figures of Reflux Pharmaceuticals Private Limited, the primary company behind Reflux Pharmaceuticals, for FY 2025. Revenue was ₹20.56 Cr (+15% year on year). Net profit was ₹57.3 Lakh (3% margin). EBITDA was ₹98 Lakh (5% margin). Revenue has grown at a compounded annual rate of +5% over three years.
- ₹20.56 CrRevenue · FY 2025 · +15% YoY
- ₹57.3 LakhNet profit · 3% margin
- ₹98 LakhEBITDA · 5% margin
- ₹76.8 LakhPaid-up capital
- +5%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Reflux Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Reflux Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Reflux Pharmaceuticals
2 dated milestones of Reflux Pharmaceuticals across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Reflux Pharmaceuticals is founded.
- Funding First funding round.
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Reflux Pharmaceuticals (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 89.42 M | 962 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 5,180 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.21 B | 25,870 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reflux Pharmaceuticals
Complete news archive for Reflux Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reflux Pharmaceuticals
Reflux Pharmaceuticals was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Reflux Pharmaceuticals is headquartered in Navi Mumbai, India. It is registered at Navi Mumbai, Maharashtra, India.
The primary company behind Reflux Pharmaceuticals, Reflux Pharmaceuticals Private Limited, reported revenue of ₹20.56 Cr for FY 2025, up 15% year on year.
Reflux Pharmaceuticals was established in 2020 and is based in Navi Mumbai, India. The company operates within the pharmaceutical sector, focusing on the production of active pharmaceutical ingredients (APIs) and chemical intermediates. These materials are supplied to support drug manufacturing processes. Operations emphasize quality-controlled synthesis and formulation, serving clients in the global healthcare industry. The firms activities align with regulatory standards for pharmaceutical components.
Reflux Pharmaceuticals offers Tolfenamic Acid and Flavoxate HCl.
Reflux Pharmaceuticals has 1 investor. Key investors include Eiko LifeSciences Limited.
Reflux Pharmaceuticals operates through Reflux Pharmaceuticals Private Limited.
The legal entities of Reflux Pharmaceuticals currently have 3 directors, including Jaid Ismail Kojar, Amit Kumar Ghosh, Sandeep Khandu Tekle.